Center for Precision Medicine, Seoul National University Hospital, Seoul, Korea.
Ewha Womans University Graduate School of Medicine, Seoul, Korea.
Cancer Med. 2018 Dec;7(12):5889-5900. doi: 10.1002/cam4.1811. Epub 2018 Nov 26.
To compare overall survival (OS) in locally advanced hypopharyngeal cancer treated with surgery or definitive chemoradiotherapy in the contemporary era.
From 2010 to 2015, data for patients diagnosed with hypopharyngeal cancer (T2-T4aM0) and treated with total pharyngectomy with lymph node dissection (surgery group) or definitive radiotherapy and chemotherapy (chemoradiotherapy group) was retrieved from the SEER database. Multivariate analyses were performed in each subgroup divided according to T category (T2-3 or T4a).
The number of patients in the surgery and chemoradiotherapy groups was 209 and 648, respectively. Among them, the number of T4a patients was 111 and 126 in each group. Three-year OS rate in the surgery and chemoradiotherapy groups was 37.9% and 44.1%, respectively (P = 0.178). The 3-year OS rate for the T2-3 patients was 46.5% and 48.7% (P = 0.598), and the 3-year OS rate for the T4a patients was 29.9% and 26.1% in the surgery and chemoradiotherapy groups, respectively (P = 0.439). On multivariate analysis, the chemoradiotherapy group was not inferior to the surgery group in T2-T4a patients (Hazard ratio [HR] for the chemoradiotherapy group 0.889, 95% confidence interval [CI] 0.699-1.129, P = 0.334), in T2-3 patients (HR 0.932, 95% CI 0.699-1.297, P = 0.675), and in T4a patients (HR 0.880, 95% CI 0.617-1.256, P = 0.481).
Chemoradiotherapy for locally advanced hypophagyngeal cancer showed a comparable OS rate to surgery. For patients with T4a category cancer with high possibility of preserving the laryngopharyngeal function, chemoradiotherapy may be a promising alternative treatment.
比较局部晚期下咽癌患者接受手术或根治性放化疗的总生存率(OS)。
从 2010 年到 2015 年,从 SEER 数据库中检索了诊断为下咽癌(T2-T4aM0)并接受全咽切除术加淋巴结清扫术(手术组)或根治性放化疗(放化疗组)的患者的数据。对根据 T 分期(T2-3 或 T4a)划分的每个亚组进行多变量分析。
手术组和放化疗组的患者人数分别为 209 人和 648 人,其中每组 T4a 患者人数为 111 人和 126 人。手术组和放化疗组的 3 年 OS 率分别为 37.9%和 44.1%(P=0.178)。T2-3 患者的 3 年 OS 率分别为 46.5%和 48.7%(P=0.598),T4a 患者的 3 年 OS 率分别为 29.9%和 26.1%手术和放化疗组(P=0.439)。多变量分析显示,在 T2-T4a 患者中,放化疗组并不劣于手术组(放化疗组的危险比 [HR]为 0.889,95%置信区间 [CI]为 0.699-1.129,P=0.334),在 T2-3 患者中(HR 为 0.932,95%CI 为 0.699-1.297,P=0.675)和 T4a 患者(HR 为 0.880,95%CI 为 0.617-1.256,P=0.481)。
局部晚期下咽癌的放化疗显示出与手术相当的 OS 率。对于有保留喉咽功能可能的 T4a 类癌症患者,放化疗可能是一种有前途的替代治疗方法。